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tive polymerase chain reaction (PCR – Taqman) as previouslyuman Adenovirus (HAdV) commonly causes mild clinical
ymptoms in immunocompetent patients. In immunocom-
romised individuals, such as patients submitted to allogeneic
tem cell transplantation (aSCT), HAdV infection can cause
rolonged and disseminated disease, resulting in a worse
rognosis for the patient or even death.1
A 57-year-old Brazilian man  was diagnosed with chronic
yeloid leukemia and during treatment with imatinib he
eveloped resistance secondary to a T315I mutation in the
CR-ABL kinase domain. A human leukocyte antigen (HLA)-
dentical sibling donor was available, and the patient was sub-
itted to stem cell transplantation in October 2012 with non-
yeloablative conditioning based on ﬂudarabine (150 mg/m2)
nd busulfan (16 mg/kg). Trimethoprim/sulfamethoxazole,
cyclovir and ﬂuconazole were given as antimicrobial pro-
hylaxis. Graft-versus-host disease (GVHD) prophylaxis wasPlease cite this article in press as: Santos HC, et al. Detection of Human Ad
tation recipient: a case report. Rev Bras Hematol Hemoter. 2016. http://dx.
chieved with cyclosporine (3 mg/kg) from Day 1 prior to trans-
lant (D − 1) and a short course of methotrexate (15 mg/m2
n D + 1 and 10 mg/m2 on D + 3, D + 6, D + 11 post-transplant).
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pen  access article under the CC BY-NC-ND license (http://creativecomCell source was non-stimulated bone marrow and 2.8 × 108/kg
of total nucleated cells without ABO incompatibility were
infused.
This study was approved by the Research Ethics Commit-
tee of the Hospital Araújo Jorge/Associac¸ão de Combate ao
Câncer em Goiás (ACCG: protocol #108.396). The patient signed
a consent form for his clinical samples (feces and sera) to
be monitored for gastroenteric viruses. The ﬁrst sample was
collected on D + 1, and subsequently samples were obtained
weekly until patient discharge. Samples were then collected
during outpatient visits. Samples were processed using com-
mercial kits (QIAamp Stool Mini Kit and QIAamp MinElute Spin
Kit, QIAGEN, Freigburg, Germany for stool and serum, respec-
tively), following the manufacturer’s instructions.
To screen for HAdV, samples were subjected to quantita-enovirus (species-C, -D and -F) in an allogeneic stem cell transplan-
doi.org/10.1016/j.bjhh.2016.09.006
de Federal de Goiás, Rua 235, s/n, sala 420, Setor Universitário,
described with adaptations.2,3 Brieﬂy, pure and 1:10 diluted
DNA was added to a 25 L mix  containing 1× of Master Mix
(applied Biosystems), 0.9 M of each primer and 0.225 M of
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/).
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Table 1 – Viral load of HAdV-positive samples and associated clinical symptoms.
Clinical sample Days after transplant qPCR (copies/mL) Species Clinical symptoms
Serum D + 9 2.07 × 106 F Vomit, abdominal pain, mucositis, diarrhea, NoV+
Stool D + 17 1.97 × 108 D Vomit, diarrhea, NoV+
Serum D + 76 3.78 × 104 F Cutaneous rash
Serum D + 153 5.79 × 104 C Diarrhea
rom D
qPCR: quantitative polymerase chain reaction; NoV: norovirus.
Grade II graft-versus-host disease of the skin and liver was present f
Taqman probes labeled with FAM-TAMRA, targeting a region
of 72 base pairs. The cycling program was the following:
50 ◦C for 1 min, 95 ◦C for 10 min, followed by 45 cycles of
95 ◦C for 15 s and 60 ◦C for 1 min. Samples were run with
standard curves (R >0.98) constructed using serial dilutions
(10−2 to 108) of the pBR322 plasmid containing the HAdV hexon
gene. Results are expressed as genomic copies per milliliter
(copies/mL).
HAdV-positive samples were also subjected to genomic
sequencing in an automatic sequencer (DNA ABI PRISM 3130,
Applied Biosystems), using puriﬁed nested-PCR products, in
duplicates, ampliﬁed by primers targeting a conserved region
of the hexon gene, as described by Puig et al.4
The samples from days D + 1, D + 3 and D + 6 were negative,
and the patient remained asymptomatic until D + 9, when he
presented nausea, vomit, abdominal pain, fever and diarrhea.
At this time, the patient also presented severe leucopenia
(<1000 cells/mm3) and lymphopenia (<300 cells/mm3). HAdV
species F was detected in serum (GenBank accession number
KP894106) with a viral load of 2.07 × 106 copies/mL (Table 1).
This sample was also positive for norovirus GI.3 identiﬁed by
reverse transcription PCR.5 The patient still presented with
diarrhea, leucopenia and lymphopenia on D + 17, and his fecal
sample tested positive for HAdV species D (GenBank accession
number KP894104) with a viral load of 1.97 × 108 copies/mL.
This sample was also positive for norovirus GI.3.
On D + 21, the patient was discharged. A fecal sample
obtained during an outpatient visit on D + 27 was positive
for HAdV (6.94 × 1010 copies/mL) and for norovirus (GI.3); at
the time the patient presented with diarrhea, abdominal
pain and vomit. The patient returned on D + 41 with a skin
rash, vomit, fever and abdominal pain; a clinical examina-
tion revealed an acute skin rash (<25% of body surface area)
and hyperbilirubinemia (3.14 mg/dL) compatible with acute
grade II GVHD. After readmission, the patient was submit-
ted to intravenous rehydration and immunosuppression with
cyclosporine (3 mg/kg) and metilprednisolone (2 mg/kg). After
ﬁve days, the patient’s clinical status had improved and the
symptoms ceased. He was discharged with a prescription
of oral cyclosporine (10 mg/kg) and prednisone (1 mg/kg). At
this time, samples were negative for HAdV, but positive for
norovirus GI.3.
On D + 76, the patient still presented with acute GVHD, and
showed positivity for HAdV species F (3.78 × 104 copies/mL) in
a serum sample. Phylogenetic analysis revealed that the HAdVPlease cite this article in press as: Santos HC, et al. Detection of Human Ad
tation recipient: a case report. Rev Bras Hematol Hemoter. 2016. http://dx.
sequence was identical to the sequence found in the sample
obtained on D + 9. Progressive reduction of prednisone was
made and interrupted on D + 108. Cyclosporine was reduced
and removed on D + 180. + 41 to D + 76.
On D + 153, the patient was suffering from diarrhea and
presented positivity for HAdV species C in serum (GenBank
accession number KP894102; 5.79 × 104 copies/mL). Subse-
quent samples were negative for HAdV and norovirus, and the
patient remained asymptomatic and without signs of GVHD.
On D + 180 after aSCT he was in complete remission and a
study of short tandem repeats (STR) showed chimerism com-
patible with 100% of donor cells and quantitative BCR-ABL
transcript negative in peripheral blood. More  than three years
after transplant, the patient remains alive without immuno-
suppression.
Discussion
HAdV infection may result in a worse prognosis for patients
submitted to aSCT.6 In some cases, HAdV infection is clinically
diagnosed as GVHD, and the use of immunosuppressive ther-
apy in these cases could further impair the patient’s clinical
condition.7 In this case, three different species of HAdV were
identiﬁed in samples from the same patient up to D + 153.
During the period in which the patient was positive for
HAdV species F and D, even though he presented symptoms
that are characteristic of enteric HAdV infection (diarrhea,
abdominal pain and vomit), he was also positive for norovirus,
which may have inﬂuenced and perhaps intensiﬁed the symp-
toms.
After a sequence of negative sera samples, one sample
was positive for HAdV species F on D + 76 that had an iden-
tical sequence to the sample detected on D + 9, this time
with lower viral load, suggesting that viremia was inter-
mittent. At this time, we were unable to differentiate viral
reactivation from persistent acute GVHD. We hypothesize that
the immunosuppressive therapy impaired viral clearance due
to the early transplantation phase associated with supposi-
tional delay in T-cell immune reconstitution. This could be
owing to inefﬁcient thymopoiesis, probably caused by the
intensive conditioning regimen, acute GVHD, use of cortico-
steroids and the recipient’s age.
Although HAdV species F may cause gastroenteritis, the
virus was not detected in fecal samples of this patient, nor
did the patient present gastroenteric symptoms when HAdV
was again detected in serum. HAdV species D, detected on
D + 17, has been associated with gastroenteritis, and may have
induced the symptoms during the time that fecal samplesenovirus (species-C, -D and -F) in an allogeneic stem cell transplan-
doi.org/10.1016/j.bjhh.2016.09.006
remained positive. HAdV species C, detected on D + 153, can
cause not only diarrhea but also respiratory and urinary symp-
toms; the latter symptoms were not observed in this case.
The asymptomatic HAdV infections have been observed in
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ransplanted patients with high viral loads, indicating that
nfection does not always necessarily cause symptoms.8
This case report shows that distinct HAdV species may be
resent in the nosocomial environment, and despite having
trict infection and transmission control measures, they are
ot always sufﬁcient to avoid viral circulation in the hospital,
s previously observed.9
This patient was the ﬁrst in a series of patients moni-
ored for HAdV infection (unpublished data). In the patients
hat followed, HAdV species F and C, with identical genomic
equences as found in the samples of this patient, were also
etected. Therefore, we  speculate that he was either the ﬁrst
atient to become HAdV-positive in a series of cases, or that
e may have been the original carrier who introduced these
iruses into the hospital, which remained circulating for at
east two more  years (data unpublished). It is also possible that
AdV-positivity is a result of adenovirus reactivation from a
reviously latent infection.10
The results highlight that HAdV can be present in the
osocomial environment, with the possibility of it remaining
nfectious for months after its ﬁrst introduction, and that
xisting infection prevention protocols are not sufﬁcient to
revent virus circulation. In Brazil, patients undergoing aSCT
re not monitored for HAdV infection, but our data demon-
trate the importance of monitoring clinical samples of these
atients in order to provide an appropriate treatment when
he infection and the clinical symptoms are present.
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